BELVIN MARCIA 4
4 · CytomX Therapeutics, Inc. · Filed Aug 22, 2024
Insider Transaction Report
Form 4
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-08-20+11,250→ 179,829 total - Exercise/Conversion
Performance Stock Units (PSUs)
2024-08-20−11,250→ 0 total→ Common Stock (11,250 underlying) - Sale
Common Stock
2024-08-20$1.23/sh−4,181$5,139→ 175,648 total
Footnotes (4)
- [F1]Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
- [F2]Includes 109,166 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
- [F4]Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.